Novo Nordisk, Gilead, BMS and AstraZeneca will feel the most pain from Biden's pricing bill: analysts

Don’t doubt the biopharma industry’s ability to find ways to circumvent the effects of the Inflation Reduction Act, signed last month by President Joe Biden.

But just imagine for a moment that the IRA works as it is designed, with insulin price caps, penalties for raising prices beyond the pace of inflation, negotiation for the drugs Medicare spends the most on and more.